Article thumbnail
Location of Repository

Verification of the Combimatrix influenza detection assay for the detection of influenza A subtype during the 2007–2008 influenza season in Toronto, Canada

By Shelly Bolotin, Ernesto Lombos, Rani Yeung, AliReza Eshaghi, Joanne Blair and Steven J Drews

Abstract

The increase in adamantine resistance in influenza A (H3N2) and the emergence of oseltamivir resistance in influenza A (H1N1) has necessitated the use of rapid methodologies to detect influenza subtype. The purpose of this study was to evaluate the CombiMatrix influenza detection system compared to the FDA approved Luminex Respiratory virus panel (RVP) assay for influenza A subtyping. Verification of the CombiMatrix influenza detection system was carried out using the Luminex RVP assay as a reference method. A limit of detection (LOD) series was performed using the Luminex and CombiMatrix systems with both influenza A H3N2 and H1N1 viruses. Seventy-five clinical specimens were used in the study. Of these, 16 were influenza A (H3N2) positive and five were influenza A (H1N1) positive. Fifty-four specimens were influenza A negative or "no call" (inconclusive) or could not be subtyped. The LOD of the Luminex RVP assay was found to be 0.3 TCID50s/mL for influenza A (H3N2) and 16 TCID50s/mL for influenza A (H1N1). The LOD of the CombiMatrix influenza detection system was 200 TCID50s/mL for influenza A (H3N2) and 16 000 TCID50s/mL for influenza A (H1N1). The sensitivity of the CombiMatrix influenza detection system was 95.2% and the specificity was 100%. The CombiMatrix influenza detection system is an effective methodology for influenza A subtype analysis, specifically in laboratories with a constrained budget or limited molecular capabilities

Topics: Short Report
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2664794
Provided by: PubMed Central

Suggested articles

Citations

  1. (2008). Against the proposition: for the diagnosis of viral infections, commercial assays provide more reliable results than do in-house assays. Rev Med Virol
  2. (2000). Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples.
  3. (2007). CombiMatrix oligonucleotide arrays: genotyping and gene expression assays employing electrochemical detection. Biosens Bioelectron
  4. (2007). Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay.
  5. (2006). et al.: Use of semiconductor-based oligonucleotide microarrays for influenza a virus subtype identification and sequencing.
  6. (2008). For the proposition: for the diagnosis of viral infections, commercial assays provide more reliable results than do in-house assays. Rev Med Virol
  7. (2008). Fox JD: Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections.
  8. (2008). Gubareva LV: Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004–2008. Antimicrob Agents Chemother
  9. (2002). Influenza virus types and subtypes detection by single step single tube multiplex reverse transcriptionpolymerase chain reaction (RT-PCR) and agarose gel electrophoresis.
  10. (2006). Klimov AI: Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA
  11. (2008). SJ: Validation of the TaqMan Influenza A Detection Kit and a rapid Automated Total Nucleic Acid Extraction Method for the Detection of Influenza A Virus from Nasopharyngeal Specimens. Ann Clin Lab Sci

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.